Vertex and Genomics plc forms a three-year collaboration extendable up to five years for Precision Medicines

 Vertex and Genomics plc forms a three-year collaboration extendable up to five years for Precision Medicines

Vertex and Genomics plc forms a three-year collaboration extendable up to five years for Precision Medicines

Shots:
  • This collaboration plans to use human genetics and machine learning to address unmet needs by developing precision medicines
  • Vertex will make £25M series B funding in Genomics (£10.5M equity investment) in addition to milestone and royalty payments from clinical developments to Genomics
  • Genomics with its largest unique analysis engine having 100B data points linking human genetic variation over 14M position in human genome to changes in 7k disease outcomes

Click here to read full press release/ article | Ref: Vertex | Image:  Xconomy

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post